JUN 18, 2014 12:00 AM PDT

Penn Study Describes New Models To Test Immune-based Drugs for Parkinson's Disease

Using powerful, newly developed cell culture and mouse models of sporadic Parkinson's disease (PD), a team of researchers from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia is attempting to show how the disease spreads from neuron to neuron. The research, which appears in Cell Reports, could be the key to finding treatments, they say.

The team has demonstrated that immunotherapy with specifically targeted antibodies may block the development and spread of PD pathology in the brain. By intercepting the distorted and misfolded alpha-synuclein (?-syn) proteins that enter and propagate in neurons, thus creating aggregates, the researchers prevented the development of pathology and also reversed some of the effects of already-existing disease. The ?-syn clumps, called Lewy bodies, eventually kill affected neurons, which leads to clinical PD.

Previous studies by senior author Virginia M.Y. Lee, PhD, and her colleagues at Penn's Center for Neurodegenerative Disease Research (CNDR) had demonstrated a novel pathology of PD in which misfolded ?-syn fibrils initiate and propagate Lewy bodies via cell-to-cell transmission. This was accomplished using synthetically created ?-syn fibrils that allowed the researchers to observe how Parkinson's pathology developed and spread in a mouse and in neurons in a dish. The current study is a proof-of-concept of how these models might be used to develop new PD therapies.

"Once we created these models, the first thing that came to mind is immunotherapy," says Lee, CNDR director and professor of pathology and laboratory medicine. "If you can develop antibodies that would stop the spreading, you may have a way to at least retard the progression of PD." The current study uses antibodies that were generated and characterized at CNDR previously to see if they would reduce the pathology both in cell culture and in animal models.

Lee's team focused on anti-?-syn monoclonal antibodies (MAbs). She explained, "In animal models, the question we want to ask is, can we reduce the pathology and also rescue cell loss to improve the behavioral deficits?"

Using their previously established sporadic PD mouse model, the researchers conducted both prevention and intervention preclinical studies. For prevention studies, they injected mouse ?-syn synthetic preformed fibrils into wild-type, normal mice, as a control, and then immediately treated the mice with Syn303, one of the MAbs used (or IgG , another type of common antibody, for the control mice).

The control group without MAb administration showed PD pathology in multiple brain areas over time, while the mice treated with Syn303 showed significantly reduced pathology in the same areas. For intervention studies, they treated PD mice with Syn303 several days after fibril injections when Lewy bodies were already present. They found that the progression of pathology was markedly reduced in the Syn303-treated mice versus mice that did not receive Syn303.

"But there are some limitations to experiments in live mice since it is difficult to directly study the mechanism of how it works," Lee said. "To do that, we went back to the cell culture model to ask whether or not the antibody basically prevents the uptake of misfolded ?-syn." The cell culture experiments showed that MAbs prevented the uptake of misfolded ?-syn fibrils by neurons and sharply reduced the recruitment of natural ?-syn into new Lewy body aggregates.

The next steps for the team will be to refine the immunotherapeutic approach. "We need to make better antibodies that have high affinity for pathology and not the normal protein," said Lee.

The team's models also open up new opportunities for studying and treating PD. "The system really allows us to identify new targets for treating PD," Lee added. "The cell model could be a platform to look for small molecular drugs that would inhibit pathology." Their approach could also serve as a foundation for genetically based studies to identify specific genes involved in PD pathology.

"Hopefully more people will use the model to look for new targets or screen for treatments for PD. That would be terrific," concluded Lee.

The work was supported by an National Institute on Aging training grant (T32-AG000235), the National Institute of Neurological Disorders and Stroke Morris K. Udall Parkinson's Disease Center of Excellence (P50 NS053488), the Michael J. Fox Foundation, the Keefer family, and the Parkinson Council. Coauthors, all from Penn, are Hien T. Tran, Charlotte Hiu-Yan Chung, Michiyo Iba, Bin Zhang, John Q. Trojanowski, and Kelvin C. Luk.

Image: Lewy body (brown) from the brain of a Parkinson's disease patient.
Credit: Kelvin Luk, PhD, Virginia Lee, PhD, Perelman School of Medicine
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 17, 2019
Drug Discovery
SEP 17, 2019
Miracle Drug for Rare Genetic Disease Causes Price Concerns
A newly approved “miracle drug” called Zolgensma will be used to treat children with spinal muscular atrophy, or SMA. Unfortunately, the therap...
SEP 17, 2019
Genetics & Genomics
SEP 17, 2019
Anorexia is Caused by Genetics and Gut Bacteria
Although usually considered a purely psychiatric disorder, recent research has uncovered that anorexia nervosa may have other underlying causes. From genet...
SEP 17, 2019
Drug Discovery
SEP 17, 2019
The Composition of Cerebrospinal Fluid in MS patients Could Be The Key To Treatments That Halt Progression
The range of disability for individuals living with multiple sclerosis (MS) varies significantly depending on the relapsing/remitting form of the disease....
SEP 17, 2019
Cell & Molecular Biology
SEP 17, 2019
Insight Into a Common Mechanism Underlying Some Neurodevelopmental Disorders
Mutations impacting a protein complex called SWI/SNF can cause a variety of problems. Now researchers know more about why....
SEP 17, 2019
Health & Medicine
SEP 17, 2019
25 Interesting Facts About The Brain
The human brain is the most complex and least-understood part of the our body. With 86 billion brain cells and as many as 10,000 specific types of neurons, it can send and receive an enormous...
SEP 17, 2019
Drug Discovery
SEP 17, 2019
How Does Ecstasy Treat PTSD?
Conventionally, Post Traumatic Stress Disorder (PTSD) is treated via talk therapy, with the aim of getting patients to open up about their trauma and rewir...
Loading Comments...